isletilmi

Isletilmi is a medication used to treat type 2 diabetes. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. The active ingredient in isletilmi is linagliptin. This medication works by increasing the levels of incretin hormones, which help to lower blood sugar levels by stimulating the pancreas to produce more insulin and by reducing the amount of glucose produced by the liver.

Isletilmi is typically taken once daily, with or without food. It is available in tablet form and is usually prescribed as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. The medication is generally well-tolerated, but like all medications, it can cause side effects. Common side effects include nausea, diarrhea, and upper respiratory tract infections. Serious side effects are rare but can include pancreatitis and increased risk of fractures.

Isletilmi was approved by the U.S. Food and Drug Administration (FDA) in 2010. It is marketed under the brand name Jentadueto. The drug is available in various countries around the world and is often used as part of a comprehensive treatment plan for type 2 diabetes. Patients should follow their healthcare provider's instructions for dosage and usage, and any side effects should be reported to a healthcare professional.